Overview

* Geron ( GERN ) Q2 product revenue rises to $49 mln, driven by RYTELO sales

* Net loss narrows sharply to $16.4 mln, operating income beats estimates

* Harout Semerjian appointed as new President and CEO

Outlook

* Geron ( GERN ) maintains 2025 operating expenses guidance of $270 mln to $285 mln

* Company expects existing cash and RYTELO sales to fund operations

* Geron ( GERN ) plans RYTELO launch in select EU countries in 2026

* IMpactMF trial full enrollment expected by year-end 2025

Result Drivers

* RYTELO SALES - Achieved $49 mln in net product revenue for Q2 2025, a 24% increase from Q1, driven by increased demand from new patient starts

* COMMERCIAL EXPANSION - Expanded sales team by 20% and doubled medical science liaisons to boost RYTELO adoption

* EU LAUNCH PREPARATION - Preparing for RYTELO launch in select EU countries following recent approval

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $49.01

Product mln

Revenue

Q2 EPS -$0.02

Q2 Net -$16.38

Income mln

Q2 Beat -$12.45 -$20 mln

Operatin mln (9

g Income Analysts

)

Q2 $61.49

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Geron Corp ( GERN ) is $4.00, about 70% above its August 5 closing price of $1.20

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)